Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor Reports Third Quarter 2025 Financial Results
04:01pm, Wednesday, 05'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor (XNCR) Projected to Post Earnings on Wednesday
04:23am, Tuesday, 04'th Nov 2025
Xencor (NASDAQ: XNCR - Get Free Report) is expected to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Xencor to post earnings of ($0.72) per share and rev
Xencor, Inc. (NASDAQ:XNCR ) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma October 24, 2025 1:30 PM EDT Company Participants Charles Liles -
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will hos
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release
05:35pm, Friday, 19'th Sep 2025
Xencor remains a "Strong Buy" rating due to progress in its bispecific and monospecific antibody pipeline targeting inflammatory disorders and cancer. XNCR's XmAb942 anti-TL1A antibody is advancing to
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
11:06am, Thursday, 18'th Sep 2025
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Xencor to Participate at Upcoming Investor Conferences
04:01pm, Wednesday, 27'th Aug 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 06'th Aug 2025
Xencor (XNCR) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.07 per share a year ago.
Xencor Reports Second Quarter 2025 Financial Results
04:01pm, Wednesday, 06'th Aug 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
04:01pm, Thursday, 31'st Jul 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
06:30pm, Wednesday, 07'th May 2025
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.
Xencor Reports First Quarter 2025 Financial Results
04:01pm, Wednesday, 07'th May 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
